COVID Moonshot
@covid-moonshot.bsky.social
On the ambitious mission to develop a safe, globally accessible, and affordable antiviral pill for COVID-19.
postera.ai/moonshot/
postera.ai/moonshot/
Reposted by COVID Moonshot
Great news! 🎉
Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.
🔗Read the press release here: dndi.org/press-releas...
Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.
🔗Read the press release here: dndi.org/press-releas...
September 24, 2025 at 8:40 AM
Great news! 🎉
Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.
🔗Read the press release here: dndi.org/press-releas...
Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.
🔗Read the press release here: dndi.org/press-releas...
Reposted by COVID Moonshot
Today, @griffen-ed.bsky.social explains at the Open Drug Discovery Symposium how @asapdiscovery.bsky.social has developed a hybrid intellectual property model that counterintuitively uses patents to support open science innovation and ensure affordability & global access.
🔗 shorturl.at/gMY0t
🔗 shorturl.at/gMY0t
shorturl.at
April 8, 2025 at 8:11 PM
Today, @griffen-ed.bsky.social explains at the Open Drug Discovery Symposium how @asapdiscovery.bsky.social has developed a hybrid intellectual property model that counterintuitively uses patents to support open science innovation and ensure affordability & global access.
🔗 shorturl.at/gMY0t
🔗 shorturl.at/gMY0t
Reposted by COVID Moonshot
'We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that.'
Read our full opinion piece co-authored by Ed Griffen (@griffen-ed.bsky.social) and Pascale Boulet ⤵️
cen.acs.org/pharmaceutic...
Read our full opinion piece co-authored by Ed Griffen (@griffen-ed.bsky.social) and Pascale Boulet ⤵️
cen.acs.org/pharmaceutic...
Opinion: How patents can serve the common good
We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that
cen.acs.org
April 4, 2025 at 7:38 AM
'We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that.'
Read our full opinion piece co-authored by Ed Griffen (@griffen-ed.bsky.social) and Pascale Boulet ⤵️
cen.acs.org/pharmaceutic...
Read our full opinion piece co-authored by Ed Griffen (@griffen-ed.bsky.social) and Pascale Boulet ⤵️
cen.acs.org/pharmaceutic...
Reposted by COVID Moonshot
At #ACSSpring2025, Ed Griffen of MedChemica disclosed the structure of a pancoronavirus antiviral that targets the main protease of the two different coronaviruses that cause Middle East respiratory syndrome (MERS) and COVID-19. cen.acs.org/acs-news/acs... 🧪
Antiviral unveiled that goes after multiple coronaviruses
Open-science consortium discloses its lead candidate to fight SARS-CoV-2 and MERS-CoV
cen.acs.org
March 27, 2025 at 11:21 PM
At #ACSSpring2025, Ed Griffen of MedChemica disclosed the structure of a pancoronavirus antiviral that targets the main protease of the two different coronaviruses that cause Middle East respiratory syndrome (MERS) and COVID-19. cen.acs.org/acs-news/acs... 🧪
Reposted by COVID Moonshot
📢Important announcement! Today, the @asapdiscovery.bsky.social consortium disclosed the structure of our preclinical candidate, ASAP-0017445, a promising broad-spectrum antiviral with potent activity against SARS-CoV2 and other viruses belonging to the same family. (1/10)
March 25, 2025 at 7:33 PM
📢Important announcement! Today, the @asapdiscovery.bsky.social consortium disclosed the structure of our preclinical candidate, ASAP-0017445, a promising broad-spectrum antiviral with potent activity against SARS-CoV2 and other viruses belonging to the same family. (1/10)
Reposted by COVID Moonshot
If you missed previous Antiviral Drug Discovery Open Science Forum talks, you can find videos of all of them online here:
asapdiscovery.org/forum/#past-...
asapdiscovery.org/forum/#past-...
Antiviral Drug Discovery (AViDD) Open Science Forum
A public venue to enable NIH-funded AViDD Centers to openly exchange and disseminate information in a pre-competitive fashion.
asapdiscovery.org
December 18, 2024 at 4:28 PM
If you missed previous Antiviral Drug Discovery Open Science Forum talks, you can find videos of all of them online here:
asapdiscovery.org/forum/#past-...
asapdiscovery.org/forum/#past-...
The COVID-Moonshot is an open-science, crowdsourced drug discovery initiative working to develop a straight-to-generic, accessible, and affordable #COVID19 antiviral.
Learn more: www.science.org/doi/10.1126/...
Learn more: www.science.org/doi/10.1126/...
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
An open-science effort yields a promising noncovalent inhibitor of the SARS-CoV-2 main protease.
www.science.org
November 21, 2024 at 10:28 AM
The COVID-Moonshot is an open-science, crowdsourced drug discovery initiative working to develop a straight-to-generic, accessible, and affordable #COVID19 antiviral.
Learn more: www.science.org/doi/10.1126/...
Learn more: www.science.org/doi/10.1126/...